ArticleCancer research2018
The Cytochrome P450 Slow Metabolizers CYP2C9*2 and CYP2C9*3 Directly Regulate Tumorigenesis via Reduced Epoxyeicosatrienoic Acid Production.
Abstract read
In one paragraph
Article in Cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
5.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 47 citations in OpenAlex.
- Identification of diagnostic and prognostic biomarkers in lung adenocarcinoma through integrated bioinformatics analysis and real time PCR validation.Scientific reports · 2026Article
- Article
- Silver Complexes of Miconazole and Metronidazole: Potential Candidates for Melanoma Treatment.International journal of molecular sciences · 2024Article
- Repurposing antifungal drugs for cancer therapy.Journal of advanced research · 2023Review
- SNPs Sets in Codifying Genes for Xenobiotics-Processing Enzymes Are Associated with COPD Secondary to Biomass-Burning Smoke.Current issues in molecular biology · 2023Article
- Drug-drug-gene interactions as mediators of adverse drug reactions to diclofenac and statins: a case report and literature review.Arhiv za higijenu rada i toksikologiju · 2021Review
- CYP2C9 inhibits the invasion and migration of esophageal squamous cell carcinoma via downregulation of HDAC.Molecular and cellular biochemistry · 2021Article
- Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets.Signal transduction and targeted therapy · 2021Review
- Human Family 1-4 cytochrome P450 enzymes involved in the metabolic activation of xenobiotic and physiological chemicals: an update.Archives of toxicology · 2021Review
- Structure of Cytochrome P450 2C9*2 in Complex with Losartan: Insights into the Effect of Genetic Polymorphism.Molecular pharmacology · 2020Article
- Lipid metabolism gene-wide profile and survival signature of lung adenocarcinoma.Lipids in health and disease · 2020Article
- Eicosanoids in Cancer: New Roles in Immunoregulation.Frontiers in pharmacology · 2020Review
- Pleiotropic Functions of Cytochrome P450 Monooxygenase-Derived Eicosanoids in Cancer.Frontiers in pharmacology · 2020Review
- Expression and Function of Eicosanoid-Producing Cytochrome P450 Enzymes in Solid Tumors.Frontiers in pharmacology · 2020Review
- CYP3A5 suppresses metastasis of lung adenocarcinoma through ATOH8/Smad1 axis.American journal of cancer research · 2020Article
- Impact of the acute local inhibition of soluble epoxide hydrolase on diabetic skin microcirculatory dysfunction.Diabetes & vascular disease research · 2019Article
- A Role for the Orphan Human Cytochrome P450 2S1 in Polyunsaturated Fatty AcidDrug metabolism and disposition: the biological fate of chemicals · 2019Article
- Identification of SERPINE1, PLAU and ACTA1 as biomarkers of head and neck squamous cell carcinoma based on integrated bioinformatics analysis.International journal of clinical oncology · 2019Article
- The label-free detection and distinction of CYP2C9-expressing and non-expressing cells by surface-enhanced Raman scattering substrates based on bimetallic AuNPs-AgNWs.RSC advances · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 1 country.
Lindsay N SausvilleDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio.
Mahesha H GangadhariahDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Manuel ChiusaDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Shaojun MeiDiabetes Research and Training Center, Vanderbilt University Medical Center, Nashville, Tennessee.
Shouzuo WeiDivision of Clinical Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee.
Roy ZentDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
James M LutherDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio.
Megan M ShueyDepartment of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Jorge H CapdevilaDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
John R FalckDivision of Chemistry, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-9219-7845
F Peter GuengerichDepartment of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee.ORCID 0000-0002-7458-3048
Scott M WilliamsDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, Ohio.ORCID 0000-0002-4835-9544
Ambra PozziDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. ambra.pozzi@vumc.org.
Vanderbilt University Medical Center · USVanderbilt University · USCase Western Reserve University · USHCA Healthcare · USCleveland Clinic · USThe University of Texas Southwestern Medical Center · US
Funding
TRANSPORT EFFECTS OF ARACHIDONATE METABOLITES IN PERFUSED TUBULEP01DK038226 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BROWN, NANCY J. · 1986 to 2015
$22.1MThe Laminin Receptors in Kidney FibrosisR01DK069921 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ROY ZENT · 2005 to 2026
$9.5MVanderbilt O'Brien Kidney Center - Core D - Clinical and Translational CoreP30DK114809 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WILSON, MATTHEW H · 2017 to 2021
$5.9MMetabolism of Carcinogens and Drugs by Human P450sR37CA090426 · NCI · VANDERBILT UNIVERSITY · PI GUENGERICH, F PETER · 2006 to 2015
$3.6MMetabolism of Carcinogens and Drugs by Human P450sR01GM118122 · NIGMS · VANDERBILT UNIVERSITY · PI GUENGERICH, F PETER · 2016 to 2023
$3.3MComputational Genomic Epidemiology of Cancer (CoGEC) Training ProgramT32CA094186 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Thomas Louis LaFramboise, Rong Xu · 2017 to 2026
$2.6MPrune Belly Syndrome: Mechanisms of Filamin A MutationsR01DK127589 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI BAKER, LINDA A., QIN, JUN · 2020 to 2024
$2.5MEET-Induced Cardioprotection: Role of Opioids and Nitric Oxide (NO)R01HL111392 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI AUCHAMPACH, JOHN A · 2012 to 2016
$2.2MThe P450 Epoxygenases as Pro-Oncogenic EnzymesR01CA162433 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI POZZI, AMBRA · 2012 to 2016
$1.9MMatrix receptors in chronic kidney diseaseR01DK119212 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BORZA, CORINA MARILENA, POZZI, AMBRA · 2018 to 2022
$1.7MIntegrin/TGF-beta Axis in Tubulointerstitial FibrosisR01DK095761 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI POZZI, AMBRA · 2013 to 2016
$1.4MStructure Function Analysis of Integrins alpha1beta1 and alpha2beta2R01DK083187 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SANDERS, CHARLES R, ZENT, ROY · 2010 to 2013
$1.3MBLRD VA I01 BX002025BLRD VA I01 BX002196NCI NIH HHS R01 CA162433NCI NIH HHS R37 CA090426NCI NIH HHS T32 CA094186NHLBI NIH HHS R01 HL111392NIDDK NIH HHS K23 DK081662NIDDK NIH HHS L40 DK069221NIDDK NIH HHS P01 DK038226NIDDK NIH HHS P30 DK114809NIDDK NIH HHS R01 DK069921NIDDK NIH HHS R01 DK083187NIDDK NIH HHS R01 DK095761NIDDK NIH HHS R01 DK119212NIDDK NIH HHS R01 DK127589NIGMS NIH HHS R01 GM118122
Abstract
Increased expression of cytochrome P450 CYP2C9, together with elevated levels of its products epoxyeicosatrienoic acids (EET), is associated with aggressiveness in cancer. Cytochrome P450 variants
Indexed as
AnimalsArachidonic AcidArachidonic AcidsCarcinogenesisCarcinoma, Non-Small-Cell LungCell Line, TumorCytochrome P-450 CYP2C9Cytochrome P-450 Enzyme SystemEicosanoidsEndothelial CellsHumansMicePolymorphism, Single NucleotideXenograft Model Antitumor AssaysArachidonic AcidArachidonic AcidsCYP2C9 protein, humanCytochrome P-450 CYP2C9Cytochrome P-450 Enzyme SystemEicosanoids
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.